Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Welltower Inc. Common Stock (WELL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Welltower Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Welltower Inc. Common Stock trades at $235.46 (market cap $167.30B). The key difference: Welltower Inc. Common Stock is far larger — about 171.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Welltower Inc. Common Stock pays a 1.46% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Welltower Inc. Common Stock for 6 Days on average.
| MRVI | WELL | |
|---|---|---|
Market Cap | $977.37M | $167.30B |
Volume | 2,742,564 | 3,257,988 |
Sector | Health | Real Estate |
52-Week High | $9.00 | $252.07 |
52-Week Low | $2.83 | $172.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $185.05B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
WELL trades at $230.14, down 0.07% on the day, with a bullish technical signal supported by moving averages and a strong ADX trend indicator. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Revenue grew to $10.67B in 2025, with net income of $936.85M, and is projected to rise to $12.6B in 2026. Analyst sentiment is strongly positive, with 71.43% buy ratings and a consensus price target of $257.08, indicating potential upside. Recent news highlights strategic acquisitions and positive coverage on senior housing demand trends.
Outlook: WELL benefits from strong demographic tailwinds in senior housing and robust analyst support, but high valuation multiples and earnings volatility pose risks. The stock's current price near support at $226 suggests a cautious entry point, with upside driven by execution on growth projections and sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Welltower Inc. Common Stock
Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →
